, Volume 37, Issue 1, pp 186–195 | Cite as

Involvement of Gr-1dull+ Cells in the Production of TNF-α and IL-17 and Exacerbated Systemic Inflammatory Response Caused by Lipopolysaccharide

  • Daiki Tanno
  • Yukiko Akahori
  • Masahiko Toyama
  • Ko Sato
  • Daisuke Kudo
  • Yuzuru Abe
  • Tomomitsu Miyasaka
  • Hideki Yamamoto
  • Keiko Ishii
  • Emi Kanno
  • Ryoko Maruyama
  • Shigeki Kushimoto
  • Yoichiro Iwakura
  • Kazuyoshi KawakamiEmail author


Systemic inflammatory response syndrome (SIRS) is a life-threatening disease. Recent reports have demonstrated that the immunoregulatory cells that express Gr-1, a granulocyte surface antigen, play a critical role in various pathological conditions. In the present study, we have established a mouse model of SIRS and addressed the possible contribution of Gr-1+ cells in this model. C57BL/6 mice were injected intraperitoneally with anti-Gr-1 mAb or control IgG 1 day before administration of lipopolysaccharide (LPS). All of the mice that received anti-Gr-1 mAb and LPS died early as a result of hypothermia and severe emaciation, whereas mice treated with control IgG and LPS survived the observation period. In mice treated with anti-Gr-1 mAb and LPS, acute inflammatory changes with alveolar hemorrhage were observed in the lung and proximal convoluted tubule necrosis was observed in the kidney. Serum TNF-α and IL-17A levels were markedly increased in anti-Gr-1 mAb-pretreated mice compared with those in control IgG-treated mice at 1 and 3 h after LPS administration, respectively. Flow cytometric analysis revealed an increase in TNF-α and IL-17A expression in Gr-1dull+ cells in the peripheral blood mononuclear cells. Neutralization of TNF-α by a specific mAb almost completely reversed the clinical course and inhibited the increased production of IL-17A. In addition, IL-17A KO mice were less susceptible to the lethality in this model. Thus, we established a mouse model of severe SIRS and suggested that Gr-1dull+ cells may play a critical role in the development of this pathological condition.


Systemic inflammatory response syndrome (SIRS) Gr-1 Lipopolysaccharide Mice 



The authors thank Dr. Fujiro Sendo (Yamagata University, Yamagata, Japan) and Dr. Akio Nakane (Hirosaki University Graduate School of Medicine, Hirosaki, Japan) for their kind gifts of anti-Gr-1 mAb and anti-TNF-α mAb, respectively. This work was supported in part by a Grant from the Ministry of Education, Culture, Sports, Science and Technology (Grant-in-Aid for Challenging Exploratory Research (23659841)) and a Grant from the Ministry of Health, Labor and Welfare of Japan (Research on Emerging and Re-emerging Infectious Diseases; 22-SHINKOU-IPPAN-014).

Conflict of interest

The authors declare that they have no financial conflicts of interest.

Supplementary material

10753_2013_9729_MOESM1_ESM.ppt (82 kb)
Fig. S1 Effect of anti-Gr-1 mAb on the expression of Gr-1 on PBMC. Mice were treated with rat IgG or anti-Gr-1 mAb, and 24 h later, PBMC were stained with anti-Gr-1 mAb and analyzed using a flow cytometry. Dotted line, rat IgG-treated; shaded area, anti-Gr-1 mAb-treated. (PPT 82 kb)


  1. 1.
    Bone, R.C., R.A. Balk, F.B. Cerra, et al. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644–55.PubMedCrossRefGoogle Scholar
  2. 2.
    Cohen, J. 2002. The immunopathogenesis of sepsis. Nature 420: 885–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Robertson, C.M., and C.M. Coopersmith. 2006. The systemic inflammatory response syndrome. Microbes and Infection 8: 1382–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Fink, M.P., and S.O. Heard. 1990. Laboratory models of sepsis and septic shock. Journal of Surgical Research 49: 186–96.PubMedCrossRefGoogle Scholar
  5. 5.
    Takeuchi, O., and S. Akira. 2001. Toll-like receptors; their physiological role and signal transduction system. International Immunopharmacology 1: 625–35.PubMedCrossRefGoogle Scholar
  6. 6.
    Salomao, R., M.K. Brunialti, M.M. Rapozo, et al. 2012. Bacterial sensing, cell signaling, and modulation of the immune response during sepsis. Shock 38: 227–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Egan, C.E., W. Sukhumavasi, A.L. Bierly, et al. 2008. Understanding the multiple functions of Gr-1+ cell subpopulations during microbial infection. Immunologic Research 40: 35–48.PubMedCrossRefGoogle Scholar
  8. 8.
    Delano, M.J., P.O. Scumpia, J.S. Weinstein, et al. 2007. MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis. Journal of Experimental Medicine 204: 1463–74.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Sawanobori, Y., S. Ueha, M. Kurachi, et al. 2008. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 111: 5457–66.PubMedCrossRefGoogle Scholar
  10. 10.
    Bronte, V., E. Apolloni, A. Cabrelle, et al. 2000. Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood 96: 3838–46.PubMedCentralPubMedGoogle Scholar
  11. 11.
    Ezernitchi, A.V., I. Vaknin, L. Cohen-Daniel, et al. 2006. TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. Journal of Immunology 177: 4763–72.CrossRefGoogle Scholar
  12. 12.
    Gómez-García, L., L.M. López-Marín, R. Saavedra, et al. 2005. Intact glycans from cestode antigens are involved in innate activation of myeloid suppressor cells. Parasite Immunology 27: 395–405.PubMedCrossRefGoogle Scholar
  13. 13.
    Goris, R.J.A. 1996. MODS/SIRS: Result of an overwhelming inflammatory response. World Journal of Surgery 20: 418–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Schlag, G., and H. Real. 1996. Mediators of injury and inflammation. World Journal of Surgery 20: 406–10.PubMedCrossRefGoogle Scholar
  15. 15.
    Thomas, J.R., J.M. Harlan, C.L. Rice, et al. 1992. Role of leukocyte CD11/CD18 complex in endotoxic and septic shock in rabbits. J App Physiol 73: 1510–6.Google Scholar
  16. 16.
    Nakae, S., Y. Komiyama, A. Nambu, et al. 2002. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17: 375–87.PubMedCrossRefGoogle Scholar
  17. 17.
    Iwakura, Y., S. Nakae, S. Saijo, et al. 2008. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunology Reviews 226: 57–79.CrossRefGoogle Scholar
  18. 18.
    de Jong, H.K., T. van der Poll, and W.J. Wiersinga. 2010. The systemic pro-inflammatory response in sepsis. Journal of Innate Immunity 2: 422–30.PubMedCrossRefGoogle Scholar
  19. 19.
    Buras, J.A., B. Holzmann, and M. Sitkovsky. 2005. Animal models of sepsis: Setting the stage. Nature Reviews Drug Discovery 4: 854–65.PubMedCrossRefGoogle Scholar
  20. 20.
    Deitch, E.A. 1998. Animal models of sepsis and shock: A review and lessons learned. Shock 9: 1–11.PubMedCrossRefGoogle Scholar
  21. 21.
    Auffray, C., M.H. Sieweke, and F. Geissmann. 2009. Blood monocytes: Development, heterogeneity, and relationship with dendritic cells. Annual Review of Immunology 27: 669–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Serbina, N.V., T. Jia, T. Hohl, et al. 2008. Monocyte-mediated defense against microbial pathogens. Annual Review of Immunology 26: 421–52.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Sunderkotter, C., T. Nikolic, M.J. Dillon, et al. 2004. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. Journal of Immunology 172: 4410–7.CrossRefGoogle Scholar
  24. 24.
    Palframan, R.T., S. Jung, G. Cheng, et al. 2001. Inflammatory chemokine transport and presentation in HEV: A remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. Journal of Experimental Medicine 194: 1361–73.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Aoyagi, T., N. Yamamoto, M. Hatta, et al. 2011. Activation of pulmonary invariant NKT cells leads to exacerbation of acute lung injury caused by LPS through local production of IFN-γ and TNF-α by Gr-1+ monocytes. International Immunology 23: 97–108.PubMedCrossRefGoogle Scholar
  26. 26.
    Deitch, E.A. 1995. Tumor necrosis factor as the proximal mediator of sepsis: Or this too will pass. Critical Care Medicine 23: 1457–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Bone, R.C. 1996. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation. Critical Care Medicine 24: 163–72.PubMedCrossRefGoogle Scholar
  28. 28.
    Beutler, B., I.W. Milsark, and A.C. Cerami. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869–71.PubMedCrossRefGoogle Scholar
  29. 29.
    Tracey, K.J., Y. Fong, D.G. Hesse, et al. 1987. Anti-cachectin/TNF-α monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Hinshaw, L.B., T.E. Emerson Jr., F.B. Taylor Jr., et al. 1992. Lethal Staphylococcus aureus-induced shock in primates: Prevention of death with anti-TNF-α antibody. Journal of Trauma 33: 568–73.PubMedCrossRefGoogle Scholar
  31. 31.
    Weaver, C.T., R.D. Hatton, P.R. Mangan, et al. 2007. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annual Review of Immunology 25: 821–52.PubMedCrossRefGoogle Scholar
  32. 32.
    Flierl, M.A., D. Rittirsch, H. Gao, et al. 2008. Adverse functions of IL-17A in experimental sepsis. FASEB Journal 22: 2198–205.PubMedCrossRefGoogle Scholar
  33. 33.
    Bosmann, M., J.V. Sarma, G. Atefi, et al. 2012. Evidence for anti-inflammatory effects of C5a on the innate IL-17A/IL-23 axis. FASEB Journal 26: 1640–51.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Ogiku, M., H. Kono, M. Hara, et al. 2012. Interleukin-17A plays a pivotal role in polymicrobial sepsis according to studies using IL-17A knockout mice. Journal of Surgical Research 174: 142–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Sutton, C.E., L.A. Mielke, and K.H. Mills. 2012. IL-17-producing γδ T cells and innate lymphoid cells. European Journal of Immunology 42: 2221–31.PubMedCrossRefGoogle Scholar
  36. 36.
    Passos, S.T., J.S. Silver, A.C. O'Hara, et al. 2010. IL-6 promotes NK cell production of IL-17 during toxoplasmosis. Journal of Immunology 184: 1776–1783.CrossRefGoogle Scholar
  37. 37.
    Michel, M.L., A.C. Keller, C. Paget, et al. 2007. Identification of an IL-17-producing NK1.1 iNKT cell population involved in airway neutrophilia. Journal of Experimental Medicine 204: 995–1001.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Rachitskaya, A.V., A.M. Hansen, R. Horai, et al. 2008. Cutting edge: NKT cells constitutively express IL-23 receptor and RORγt and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. Journal of Immunology 180: 5167–71.CrossRefGoogle Scholar
  39. 39.
    Bosmann, M., and P.A. Ward. 2012. Therapeutic potential of targeting IL-17 and IL-23 in sepsis. Clin Transl Med 1: 4–5.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Gu, Y., J. Yang, X. Ouyang, et al. 2008. Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. European Journal of Immunology 38: 1807–13.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Umemura, M., A. Yahagi, S. Hamada, et al. 2007. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette–Guerin infection. Journal of Immunology 178: 3786–96.CrossRefGoogle Scholar
  42. 42.
    Ouyang, W., S. Rutz, N.K. Crellin, et al. 2011. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annual Review of Immunology 29: 71–109.PubMedCrossRefGoogle Scholar
  43. 43.
    Li, M.O., Y.Y. Wan, S. Sanjabi, et al. 2006. Transforming growth factor-beta regulation of immune responses. Annual Review of Immunology 24: 99–146.PubMedCrossRefGoogle Scholar
  44. 44.
    Cavaillon, J.M., and M. Adib-Conquy. 2006. Bench-to-bedside review: Endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Critical Care 10: 233–40.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    St. John, R.C., and P.M. Dorinsky. 1993. Immunologic therapy for ARDS, septic shock, and multiple-organ failure. Chest 103: 932–43.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Daiki Tanno
    • 1
    • 2
  • Yukiko Akahori
    • 1
    • 3
  • Masahiko Toyama
    • 1
  • Ko Sato
    • 1
  • Daisuke Kudo
    • 4
  • Yuzuru Abe
    • 1
    • 5
  • Tomomitsu Miyasaka
    • 1
    • 6
  • Hideki Yamamoto
    • 1
  • Keiko Ishii
    • 1
  • Emi Kanno
    • 7
  • Ryoko Maruyama
    • 7
  • Shigeki Kushimoto
    • 4
  • Yoichiro Iwakura
    • 8
  • Kazuyoshi Kawakami
    • 1
    Email author
  1. 1.Department of Medical Microbiology, Mycology and ImmunologyTohoku University Graduate School of MedicineSendaiJapan
  2. 2.Department of Laboratory MedicineFukushima Medical University HospitalFukushimaJapan
  3. 3.Japanese Red Cross SocietyKoto-kuJapan
  4. 4.Department of Emergency MedicineTohoku University Graduate School of MedicineSendaiJapan
  5. 5.Department of Cardiovascular MedicineTohoku University Graduate School of MedicineSendaiJapan
  6. 6.Department of PathophysiologyTohoku Pharmaceutical UniversitySendaiJapan
  7. 7.Department of Science of Nursing PracticeTohoku University Graduate School of MedicineSendaiJapan
  8. 8.Research Institute for Biomedical SciencesTokyo University of ScienceNodaJapan

Personalised recommendations